Global contract research organization (CRO) providing specialty laboratory services to support the entire drug development cycle.
USA, CAN, BE, AUS, CHN
Joined November 2011
- Tweets1.4K
- Following1.1K
- Followers1K
- Likes718
Let's Talk! In our latest webcast, we discuss the realities of building and commercializing CAR-T therapies with Dr. John Rossi, a leader in the field of CAR-T therapy.
Watch the full conversation here: buff.ly/BTfbYHf
馃搶 Global Expertise + Local Presence
We're thrilled to be at AusBiotech this week - visit Pierre Gontard and Kevin Lo at Booth 118 in Gold Coast!
Drop by to discuss how we can support your local programs and global trials with our site in Sydney, global labs and expertise.
Gold Coast! We're excited to be heading to AusBiotech - come say hi at Booth 118, from October 21 to 23.
Bring your biomarker questions - from multi-modal global trials to keeping your immunology testing local, our experts are excited to discuss how we can support your programs.
Announcement! CellCarta and Tivenix are expanding their partnership.
Tivenix's AI-powered platform applies bioinformatics to the epigenetic analysis of cell-free DNA and other tissue-derived signals, supporting precision medicine applications.
Read here: buff.ly/L8RIN9p
Did we miss you in Basel? We're still available to chat! 馃憢
We're always excited to discuss the biggest challenges facing your programs, from translational research to CDx commercialization. If we missed you in Basel, send us a message to connect 鉁夛笍 buff.ly/0gMp5PK
CellCarta's Christopher Ung is the Conference Chair for this afternoon's World CB and CDx Summit sessions.
Join him for two engaging sessions covering diverse topics across clinical biomarkers and CDx development.
See you there!
We're pleased to announce a strategic partnership with Waters Corporation to advance companion diagnostics (CDx) development. buff.ly/CRDVBPf
The collaboration creates a framework to jointly pursue CDx and next-generation flow cytometry opportunities with biopharma.
including through our laboratory in China.
"By combining CellCarta's end-to-end laboratory capabilities with Waters' diagnostic and CDx development expertise, and flow cytometry platforms, we can help sponsors reduce complexity, preserve program continuity
and make earlier, more informed decisions about how to scale their programs." Todd Chermak, President, CellCarta
Read the full release: buff.ly/CRDVBPf
We're bringing the CellCarta team to Basel for an afternoon built around your biomarker challenges.
Spaces are limited, so reserve yours here: buff.ly/eUmM6Kl
馃搮Oct 7, 12:10 PM
Presentation: The CDx Model Needs to Change. What China taught us about breaking silos, moving faster and going global
馃搮Oct 8, 11:20 AM,
Presentation: Can AI Predict ADC Response? With Siraj A. of Lunit, on discovering, validating and deploying AI biomarkers faster
If you'd rather talk through your own program, the CellCarta team will be in Boston all week. Book here: buff.ly/g38Az8B
CellCarta and Imagene AI are expanding their collaboration to give biopharma a coordinated path to validate, deploy and scale AI-powered biomarker and companion diagnostic (CDx) programs.
Read the full announcement: buff.ly/EVKyNo0
Our experts head to Basel, Switzerland next month! Join us for a day of insights into biomarkers- multimodal science, practical paths to CDx development, and regulatory support to take them from innovation to impact.
Register here: buff.ly/KzWdXxt
Big News! Following recent updates to the FAMHP Q&A on in-house IVDs, CellCarta can provide EU clinical trial testing through an additional regulatory pathway under IVDR Article 5(5) when study conditions are met.
Learn more here: buff.ly/fNxmgb9
